China's National Medical Products Administration (NMPA) approved Eisai's (TYO:4523) anti-amyloid beta protofibril antibody Leqembi, or lecanemab, as an initiation treatment for mild cognitive impairment due to Alzheimer's disease or mild AD dementia.
Leqembi SC-AI is a self-administered autoinjector given once weekly at 500 mg through two 250 mg injections, according to a Thursday filing with the Japan bourse.
The approval adds at-home subcutaneous treatment to the existing every-two-week intravenous regimen, with patients able to switch between the two administration methods during treatment, the release said.
Leqembi was launched in China in June 2024, it said.
Shares of Eisai rose nearly 2% at market close.